biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Tough time in the market now...

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Feb 24, 2023 10:53am

61 Views

Post# 35303333

RE:RE:Tough time in the market now...

When 25% of biotech in general and even moreso preclinical biotech was driven below the value of cash on the balance sheet in the worst bear market in history it wasn't caused by Rathjen. Your happy talk about a preclinical biotech taking on debt before the worst biotech bear market in history was not helpful; especially given BTI was still transitioning to find a new horse after all of your happy talk about Herceptin. You talked about Herceptin. You talked up debt. Total folly.

Boomskid wrote: Lol, poof, when you're pushed back onto your hind feet, you want to talk about how "The S&P Biotech ETF had a strong move into the new year but has collapsed back to where it was when BTI was closing the Biodexa deal."

So, Bioasis is at 1.5¢ today because of inflation and because of the market that has pushed the S&P Biotech ETF down? Is that it?

You don't think, poof, that maybe the actions of the Bioasis CEO, Dr. Deborah Rathjen, and the BoD have resulted in the current share price?

Do you really expect anybody to buy that market/ETF load?

jd